Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia
Acute Myeloid Leukemia
DRUG: IBI188|DRUG: Azacitidine|DRUG: Decitabine
Composite complete rate, Composite CR including complete remission rate and morphologic complete remission with incomplete blood count recovery, 24 weeks
Cytogenetic CR, 24 weeks
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia